P.0533 Paliperidone palmitate 6-month long-acting injectable for schizophrenia: A randomised, double-blind, multicenter, noninferiority phase 3 study

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2021.10.504 ◽

2021 ◽

Vol 53 ◽

pp. S393

Author(s):

D. Najarian ◽

P. Sanga ◽

S. Wang ◽

P. Lim ◽

A. Singh ◽

...

Keyword(s):

Paliperidone Palmitate ◽

Phase 3 ◽

Double Blind ◽

Download Full-text

Withdrawal from long-acting somatostatin receptor ligand injections in adult patients with acromegaly: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study

Endocrine Abstracts ◽

10.1530/endoabs.70.aep668 ◽

2020 ◽

Author(s):

Lisa Nachtigall ◽

Susan Samson ◽

Maria Fleseriu ◽

Marek Bolanowski ◽

Molitch Mark E ◽

...

Keyword(s):

Somatostatin Receptor ◽

Adult Patients ◽

Phase 3 ◽

Double Blind ◽

Receptor Ligand ◽

Double Blind Placebo ◽

Long Acting ◽

Somatostatin Receptor Ligand

Download Full-text

Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD

10.1183/1393003.congress-2017.pa1812 ◽

2017 ◽

Author(s):

Gary Ferguson ◽

Krishna K. Pudi ◽

Gregory Feldmann ◽

Srikanth Pendyala ◽

Chris N. Barnes ◽

...

Keyword(s):

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Muscarinic Antagonist ◽

Double Blind Placebo ◽

Parallel Group ◽

Long Acting ◽

Download Full-text

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

Annals of General Psychiatry ◽

10.1186/1744-859x-10-12 ◽

2011 ◽

Vol 10 (1) ◽

pp. 12 ◽

Author(s):

Larry Alphs ◽

Cynthia A Bossie ◽

Jennifer K Sliwa ◽

Yi-Wen Ma ◽

Norris Turner

Keyword(s):

Clinical Trial ◽

Paliperidone Palmitate ◽

Double Blind ◽

Post Hoc Analysis ◽

Double Blind Clinical Trial ◽

Long Acting ◽

Download Full-text

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry ◽

10.1016/j.pnpbp.2010.11.008 ◽

2011 ◽

Vol 35 (1) ◽

pp. 218-226 ◽

Author(s):

Gahan Pandina ◽

Rosanne Lane ◽

Srihari Gopal ◽

Cristiana Gassmann-Mayer ◽

David Hough ◽

...

Keyword(s):

Blind Study ◽

Paliperidone Palmitate ◽

Double Blind Study ◽

Double Blind ◽

Download Full-text

Trial in Progress: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial to Evaluate the Safety and Tolerability of a Nebulized Long-Acting Muscarinic Antagonist (Revefenacin) in Study Participants With COPD

CHEST Journal ◽

10.1016/j.chest.2016.08.966 ◽

2016 ◽

Vol 150 (4) ◽

pp. 866A ◽

Author(s):

Luis DeLaCruz ◽

Srikanth Pendyala ◽

Chris Barnes ◽

Edmund Moran ◽

Brett Haumann ◽

...

Keyword(s):

Phase 3 ◽

Double Blind ◽

Muscarinic Antagonist ◽

Double Blind Placebo ◽

Parallel Group ◽

Long Acting ◽

Study Participants

Download Full-text

Biochemical control of most patients reverting to injectable long-acting somatostatin receptor ligands is achieved after one dose: Results from the phase 3, randomized, double blind, placebo-controlled optimal study

Endocrine Abstracts ◽

10.1530/endoabs.70.aep577 ◽

2020 ◽

Author(s):

Maria Fleseriu ◽

Susan Samson ◽

Lisa Nachtigall ◽

Artak Labadzhyan ◽

Atanaska Elenkova ◽

...

Keyword(s):

Somatostatin Receptor ◽

Receptor Ligands ◽

Biochemical Control ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Somatostatin Receptor Ligands ◽

Download Full-text

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Brazilian Journal of Psychiatry ◽

10.1590/1516-4446-2018-0153 ◽

2019 ◽

Vol 41 (6) ◽

pp. 499-510

Author(s):

Adam J. Savitz ◽

Haiyan Xu ◽

Srihari Gopal ◽

Isaac Nuamah ◽

Maju Mathews ◽

...

Keyword(s):

Latin American ◽

Subgroup Analysis ◽

Paliperidone Palmitate ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Download Full-text

307. Potential Biomarkers of Impending Schizophrenia Relapse: Exploratory Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase-3 Study of Paliperidone Palmitate 3-Month Formulation

Biological Psychiatry ◽

10.1016/j.biopsych.2017.02.322 ◽

2017 ◽

Vol 81 (10) ◽

pp. S126-S127

Author(s):

Srihari Gopal ◽

Maura Furey ◽

Derrek Hibar ◽

Hartmuth Kolb ◽

Ziad Saad ◽

...

Keyword(s):

Exploratory Analysis ◽

Paliperidone Palmitate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Potential Biomarkers

Download Full-text

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

BMC Psychiatry ◽

10.1186/1471-244x-11-79 ◽

2011 ◽

Vol 11 (1) ◽

Author(s):

Cynthia A Bossie ◽

Jennifer K Sliwa ◽

Yi-Wen Ma ◽

Dong-Jing Fu ◽

Larry Alphs

Keyword(s):

Clinical Trial ◽

Paliperidone Palmitate ◽

Double Blind ◽

Double Blind Clinical Trial ◽

Long Acting ◽

Download Full-text

Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies

Endocrine ◽

10.1007/s12020-017-1448-5 ◽

2017 ◽

Vol 60 (1) ◽

pp. 65-72 ◽

Author(s):

Rosario Pivonello ◽

Giovanna Muscogiuri ◽

Geoffrey Holder ◽

Michaela Paul ◽

Severine Sarp ◽

...

Keyword(s):

Diabetic Retinopathy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Pooled Data ◽

Download Full-text